Beta Emitting Implants for Internal Treatment Revision Notes | A Level AQA Physics

1. Why Put Radiation Inside the Body?

External radiotherapy fires a beam of radiation through healthy tissue to reach a tumour. Every centimetre of healthy tissue the beam crosses receives an unwanted dose. Beta-emitting implants solve this problem by placing the source at the tumour, so the radiation never has to travel through large volumes of healthy tissue to get there.

This approach is called brachytherapy — from the Greek word for 'short distance'. The implant sits millimetres from the cells it needs to destroy, and because beta particles have a very short range in tissue, the dose drops off sharply beyond the target volume. That sharp fall-off is the key physical property that makes beta emitters so well suited to this technique.

2. Beta Radiation: The Physics Behind the Therapy

A beta-minus particle is a fast-moving electron ejected from the nucleus when a neutron converts to a proton. It carries a charge of $-1e$ and a rest mass roughly 1/1836 that of a proton. Because it is charged and relatively light, it interacts strongly with the electrons of surrounding atoms, losing energy rapidly through ionisation and excitation along its path.

In soft tissue, beta particles from therapeutic radionuclides typically travel only 1–10 mm before coming to rest. That short range is not a limitation — it is precisely the feature that makes them therapeutically useful. The energy is deposited in a tightly confined volume around the implant, maximising dose to the tumour while sparing tissue beyond that narrow margin.

Compare this with alpha particles, which have an even shorter range and cannot penetrate the outer layers of skin — making them unsuitable for external therapy. Alpha particles do have clinical applications in targeted alpha therapy (for example, radium-223 for bone metastases), but their extremely short range makes them impractical for brachytherapy implants of the type discussed here, where the source must irradiate tumour cells a few millimetres away. Gamma rays, by contrast, travel centimetres to metres through tissue, which is why gamma-emitting sources used internally would irradiate a much larger volume of healthy tissue. Beta sits in the middle: penetrating enough to reach cells a few millimetres from the source, but not so penetrating that it irradiates distant organs.

3. How Beta-Emitting Implants Work in Practice

Picture a small tumour — say, in the prostate gland. A surgeon implants several tiny sealed capsules, each containing a beta-emitting radionuclide, directly into the tumour tissue. Each capsule is typically a few millimetres long, encased in a biocompatible metal shell (such as titanium) that is thick enough to contain the radioactive material and stop alpha particles, while remaining thin enough to allow beta particles to escape into the surrounding tissue. Bremsstrahlung X-rays produced by beta particles decelerating in matter are a minor secondary emission and are not significantly attenuated by the thin shell.

Once in place, the implants continuously emit beta particles. These particles ionise the DNA of nearby cancer cells, causing double-strand breaks that the rapidly dividing cells cannot repair efficiently. Because cancer cells divide more frequently than most healthy cells, they are disproportionately sensitive to this radiation damage — a principle known as the differential radiosensitivity of tumour tissue.

The implants may be permanent or temporary. Permanent implants use radionuclides with a short half-life, so the activity decays to a negligible level within weeks to months while the sealed capsule remains in the body harmlessly. Temporary implants are removed once the prescribed dose has been delivered. The choice depends on the tumour type, its location, and the required dose rate.

4. Choosing the Right Radionuclide

Not every beta emitter is suitable for implant therapy. The choice of radionuclide depends on three linked factors: the energy of the emitted beta particles (which determines range in tissue), the half-life (which determines how long the source remains active), and whether the decay also produces gamma rays (which would irradiate tissue far beyond the target).

A short half-life is preferred for permanent implants, where removal is not possible, so that the activity decays to a negligible level within weeks to months while the sealed capsule remains in the body harmlessly. Temporary implants may use higher-activity sources with a range of half-lives, since they are removed once the prescribed dose has been delivered — the half-life is less critical for post-removal exposure in that case. A half-life of decades (like strontium-90) would be unsuitable for a permanent internal implant because the patient would remain significantly radioactive for years.

Pure beta emitters — those that produce no accompanying gamma radiation — are particularly attractive because they minimise dose to staff, carers, and the public. Yttrium-90 is a good example: it emits only beta particles, so once the particles are absorbed in the surrounding tissue, no penetrating radiation escapes the patient's body.

5. Biological Mechanism: How Beta Radiation Destroys Tumour Cells

When a beta particle passes through tissue, it strips electrons from atoms along its path — a process called ionisation. Inside a cell, this ionisation can directly break the covalent bonds in DNA, producing single-strand or double-strand breaks. Double-strand breaks are particularly lethal because the cell's repair machinery struggles to rejoin both strands correctly.

Beta radiation also acts indirectly. Ionisation of water molecules inside the cell produces free radicals — highly reactive species such as the hydroxyl radical (OH•) — which then attack DNA, proteins, and cell membranes. This indirect mechanism accounts for roughly 60–70% of the biological damage from beta radiation in well-oxygenated tissue.

Rapidly dividing cells are most vulnerable because DNA replication exposes the strands to damage, and cells in mitosis have less time to repair breaks before the next division. Tumour cells, which divide far more frequently than most healthy cells, therefore accumulate lethal damage more quickly. This is the biological rationale for using radiation — including beta-emitting implants — as a cancer therapy.

6. Advantages and Limitations: An Evaluated Comparison

Beta-emitting implants offer several genuine clinical advantages over external beam radiotherapy. The dose is delivered continuously at a low dose rate, which gives healthy cells more time to repair sub-lethal damage between ionisation events — a phenomenon called the dose-rate effect. Tumour cells, with their impaired repair mechanisms, benefit less from this repair window, widening the therapeutic gap between tumour kill and healthy tissue sparing.

The localised geometry also means that patient movement between treatment sessions — a significant source of error in external beam therapy — is irrelevant for permanent implants. The source moves with the tumour. For prostate cancer in particular, this geometric precision has made permanent seed brachytherapy a standard treatment option with outcomes comparable to surgery.

There are, however, real limitations. Implants are only practical for accessible, well-defined tumours. Diffuse or metastatic disease cannot be treated this way. Surgical implantation carries procedural risks, and if the radionuclide also emits gamma radiation, radiation protection measures for the patient's family become necessary. Dosimetry — calculating the exact dose delivered to every part of the tumour — is also more complex than for an external beam, because the dose rate varies with distance from each seed according to an inverse-square relationship.

7. Exam Technique and Mark-Winning Guidance

AQA questions on beta-emitting implants tend to fall into two categories: explain/describe questions about the physical and biological mechanism, and evaluate questions asking you to compare this technique with alternatives. The mark schemes reward precise physical reasoning — vague answers about radiation 'killing cells' without explaining the ionisation mechanism will not score highly.

When a question asks you to explain why beta emitters are used rather than alpha or gamma emitters, structure your answer around three linked points: range in tissue, dose localisation, and penetrating radiation hazard. Alpha particles have too short a range to penetrate from an implant into surrounding tumour cells effectively, and they present a serious hazard if the source leaks. Gamma emitters would irradiate healthy tissue far beyond the tumour. Beta sits between these extremes — the range is short enough for localisation but sufficient to irradiate the tumour volume.

For evaluate questions, always reach a conclusion. State which factor is most significant and why. For example: 'The most important advantage is the short range of beta particles, because this is the physical property that underpins all the clinical benefits — localised dose, sparing of healthy tissue, and reduced radiation protection requirements for pure beta emitters.'

This lesson has covered the full specification requirement for internal treatment using beta-emitting implants: the physical basis (short range, ionisation, dose localisation), the biological mechanism (DNA strand breaks, free radical production, differential radiosensitivity), the clinical application (permanent and temporary implants, radionuclide selection, half-life considerations), and the evaluated comparison with alternative modalities. Every one of these threads can appear in an AQA exam question — and now you have the precise language to answer them.